Plain-English translation of NCT05389319 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new COVID-19 booster vaccine called . Researchers want to find the safest and most effective dose of this vaccine by giving different groups of people different amounts. The study will follow participants for 6 months after they receive one injection to see how their body responds and whether they have any side effects.
Scientists are working to develop new booster vaccines that might provide better protection against COVID-19 variants. This medication uses a different technology than most COVID-19 vaccines available today, and researchers need to understand how well it works and what dose is best before testing it in larger groups.
You likely qualify if…
You likely don't qualify if…
You will receive one injection of the vaccine on Day 1, then return for check-in visits on Days 4, 8, 15, 29, and at 3 and 6 months. The researchers will also call you on Days 2 and 3 to ask about any side effects. At each visit, they will check your health, ask about symptoms, and may take blood samples to measure how your immune system is responding to the vaccine. The entire study lasts about 6 months.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Germany
Phase
Safety & dosing
Sponsor
University Hospital Tuebingen
Collaborators
FGK Clinical Research GmbH, VisMederi srl
Enrollment target
~96 participants
Started
June 2022
Primary completion
December 2026
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
University Hospital Tübingen
University Hospital Tübingen, Institute of Tropical Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.